Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
Primary Purpose
Cerebrovascular Accident
Status
Unknown status
Phase
Phase 3
Locations
Taiwan
Study Type
Interventional
Intervention
Botulinum Toxin Type A
Sponsored by
About this trial
This is an interventional treatment trial for Cerebrovascular Accident focused on measuring stroke, upper extremity, spasticity, botulinum toxin, ultrasonography, electric stimulation
Eligibility Criteria
Inclusion Criteria:
- first onset.
- at least onset before 6 months.
- elbow, wrist and fingers are above Modified Ashworth Scale(MAS) 1+.
- Mini-Mental State Exam above 24.
- can follow all of the follow up and instruction.
- patients never accept botox, phenol and alcohol injections before.
Exclusion Criteria:
- contracture deformity on upper extremity.
- patients had accepted botox before or had have phenol, alcohol injections and operation 6 months ago.
- allergy to botox.
- have neither infection nor skin disorder on inject site.
- now accept aminoglycoside or other medicine treatment which may affect neuromuscular transition.
- combine other systemic disease of neurological or skelectomuscular system
- cognition disorder or aphasia after stroke.
Sites / Locations
- Chang Gung Memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Ultrasonography direct-guidance
Electric stimulation
Surface anatomy landmark
Arm Description
To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
Outcomes
Primary Outcome Measures
Modified Ashworth Scale
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Secondary Outcome Measures
Brunnstrome Stage
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Active Range of Motion
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
4 Point Categorical Pain Intensity Scale
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Hand-grasp strength Assessment
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Pinch Strength Assessment
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Barthel Index
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Stroke Impact Scale (SIS)
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Action Research Arm Test (ARAT)
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Wolf Motor Function Test
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Chedoke Arm and Hand Activity Inventory (CAHAI)
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Fugl-Meyer Assessment
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Motor Activity Log Scale
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Nine Hole Peg Test
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Full Information
NCT ID
NCT02557737
First Posted
September 17, 2015
Last Updated
March 28, 2016
Sponsor
Chang Gung Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02557737
Brief Title
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
Official Title
Comparison of Surface Landmark, Ultrasonography and Electric Stimulation Guidance for Botulinum Toxin Injections in Stroke Patients With Spasticity on Upper Extremities.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Unknown status
Study Start Date
September 2012 (undefined)
Primary Completion Date
July 2016 (Anticipated)
Study Completion Date
July 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aims of this study were to compare the injection locations of key spastic muscles on upper extremity by three different guidance localization methods ( surface anatomy landmark, ultrasonography, electric stimulation) and the effectiveness.
Detailed Description
Stroke may result in acute or chronic hemiplegia and spasticity in stroke patients. Spasticity in upper extremities may interfere with motor voluntary function, activities of daily living and cause muscle pain. Botulinum toxin type A (BTX-A) has been shown to relieve spasticity and pain in upper extremities of stroke patients. There are no researches to compare the efficiency of BTX-A by different injection guidance methods in stroke patients. The aims of our study were to compare the injection locations of key spastic muscles on upper extremity by three different guidance localization methods ( surface anatomy landmark, ultrasonography, electric stimulation) and the effectiveness. The investigators will enroll 60 hemiplegic stroke patients with upper extremity spasticity more than modified Ashworth scale ( MAS) 1+ and duration more than 6 months. Under different guidance methods (surface anatomy landmark/ ultrasonography /electric stimulation ), BTX-A will be injected to the key spastic muscles on upper extremity. Outcome measures include MAS, motor function ( Brunnstrom stage of upper extremity), range of motion , the degree and visual analog scale of pain , pinch and grasp power,Stroke Impact Scale, Barthel index and upper extremity function (Nine hole peg test,Action Reaearch Arm Test,Wolf Motor Function test,Chedoke Arm and Han Activity Inventory,Fugl-Meyer Assessment Scale,Motor Activity Log). All the assessments will be performed before BTX-A injection and followed up at 4 weeks, 8 weeks, 12 weeks and 24 weeks after injection. After performing all the assessments, investigators will investigate the efficiency of BTX-A by different guidance methods.
Four of arms:
ultrasonography direct-guidance: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
ultrasonography indirect-guidance: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography indirect-guidance.
electric stimulation guidance: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by electric stimulation guidance.
surface anatomy landmark: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by surface anatomy landmark.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebrovascular Accident
Keywords
stroke, upper extremity, spasticity, botulinum toxin, ultrasonography, electric stimulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ultrasonography direct-guidance
Arm Type
Experimental
Arm Description
To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
Arm Title
Electric stimulation
Arm Type
Experimental
Arm Description
To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
Arm Title
Surface anatomy landmark
Arm Type
Active Comparator
Arm Description
To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
Intervention Type
Drug
Intervention Name(s)
Botulinum Toxin Type A
Other Intervention Name(s)
Botulinum toxin
Intervention Description
To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
Primary Outcome Measure Information:
Title
Modified Ashworth Scale
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Muscle Tone at 6 months
Secondary Outcome Measure Information:
Title
Brunnstrome Stage
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Condition at 6 months
Title
Active Range of Motion
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
4 Point Categorical Pain Intensity Scale
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Hand-grasp strength Assessment
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Pinch Strength Assessment
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Barthel Index
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Stroke Impact Scale (SIS)
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Action Research Arm Test (ARAT)
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Wolf Motor Function Test
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Chedoke Arm and Hand Activity Inventory (CAHAI)
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Fugl-Meyer Assessment
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Motor Activity Log Scale
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
Title
Nine Hole Peg Test
Description
patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks after injection
Time Frame
Change from Baseline Data at 6 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
first onset.
at least onset before 6 months.
elbow, wrist and fingers are above Modified Ashworth Scale(MAS) 1+.
Mini-Mental State Exam above 24.
can follow all of the follow up and instruction.
patients never accept botox, phenol and alcohol injections before.
Exclusion Criteria:
contracture deformity on upper extremity.
patients had accepted botox before or had have phenol, alcohol injections and operation 6 months ago.
allergy to botox.
have neither infection nor skin disorder on inject site.
now accept aminoglycoside or other medicine treatment which may affect neuromuscular transition.
combine other systemic disease of neurological or skelectomuscular system
cognition disorder or aphasia after stroke.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pong Ya-Ping, MD
Phone
889-7-7317123
Ext
6286
Email
yaping0707@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pong Ya-Ping, MD
Organizational Affiliation
Rehabilitation
Official's Role
Study Chair
Facility Information:
Facility Name
Chang Gung Memorial Hospital
City
Kaohsiung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pong Ya-ping, MD
Phone
889-7-7317123
Ext
6286
Email
yaping0707@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
475355
Citation
Mizrahi EM, Angel RW. Impairment of voluntary movement by spasticity. Ann Neurol. 1979 Jun;5(6):594-5. doi: 10.1002/ana.410050620. No abstract available.
Results Reference
background
PubMed Identifier
9826984
Citation
Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997;6:S92-120.
Results Reference
background
PubMed Identifier
9826983
Citation
Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl. 1997;6:S61-91.
Results Reference
background
PubMed Identifier
12569963
Citation
Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain. 2002 Nov-Dec;18(6 Suppl):S155-62. doi: 10.1097/00002508-200211001-00007.
Results Reference
background
PubMed Identifier
15201348
Citation
Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):951-7. doi: 10.1136/jnnp.2003.034702.
Results Reference
background
PubMed Identifier
21045798
Citation
Lim EC, Seet RC. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol. 2010 Nov;6(11):624-36. doi: 10.1038/nrneurol.2010.149. Epub 2010 Oct 12.
Results Reference
background
PubMed Identifier
12167681
Citation
Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C; Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 8;347(6):395-400. doi: 10.1056/NEJMoa011892.
Results Reference
background
PubMed Identifier
17617291
Citation
Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007 Apr;29(4):683-90. doi: 10.1016/j.clinthera.2007.04.015.
Results Reference
background
PubMed Identifier
8857723
Citation
Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology. 1996 Oct;47(4):939-44. doi: 10.1212/wnl.47.4.939.
Results Reference
background
PubMed Identifier
11022071
Citation
Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000 Oct;31(10):2402-6. doi: 10.1161/01.str.31.10.2402.
Results Reference
background
PubMed Identifier
17285183
Citation
Francisco GE. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. Ann Acad Med Singap. 2007 Jan;36(1):22-30.
Results Reference
background
PubMed Identifier
15832139
Citation
Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop. 2005 May-Jun;25(3):286-91. doi: 10.1097/01.bpo.0000150819.72608.86.
Results Reference
background
PubMed Identifier
11889247
Citation
Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002 Mar 12;58(5):805-7. doi: 10.1212/wnl.58.5.805.
Results Reference
background
PubMed Identifier
16198612
Citation
Lim EC, Ong BK, Seet RC. Botulinum toxin-A injections for spastic toe clawing. Parkinsonism Relat Disord. 2006 Jan;12(1):43-7. doi: 10.1016/j.parkreldis.2005.06.008. Epub 2005 Sep 29.
Results Reference
background
PubMed Identifier
9826989
Citation
O'Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl. 1997;6:S176-80.
Results Reference
background
PubMed Identifier
20797552
Citation
Alter KE. High-frequency ultrasound guidance for neurotoxin injections. Phys Med Rehabil Clin N Am. 2010 Aug;21(3):607-30. doi: 10.1016/j.pmr.2010.05.001.
Results Reference
background
PubMed Identifier
14738817
Citation
Berweck S, Schroeder AS, Fietzek UM, Heinen F. Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet. 2004 Jan 17;363(9404):249-50. doi: 10.1016/S0140-6736(03)15351-2. No abstract available.
Results Reference
background
PubMed Identifier
16785117
Citation
Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques. Neurotox Res. 2006 Apr;9(2-3):189-96. doi: 10.1007/BF03033938.
Results Reference
background
PubMed Identifier
18560136
Citation
Depedibi R, Unlu E, Cevikol A, Akkaya T, Cakci A, Cerekci R, Kose G, Unlusoy D. Ultrasound-guided botulinum toxin type A injection to the iliopsoas muscle in the management of children with cerebral palsy. NeuroRehabilitation. 2008;23(3):199-205.
Results Reference
background
PubMed Identifier
20659720
Citation
Henzel MK, Munin MC, Niyonkuru C, Skidmore ER, Weber DJ, Zafonte RD. Comparison of surface and ultrasound localization to identify forearm flexor muscles for botulinum toxin injections. PM R. 2010 Jul;2(7):642-6. doi: 10.1016/j.pmrj.2010.05.002.
Results Reference
background
Learn more about this trial
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
We'll reach out to this number within 24 hrs